Skip to main content
Top
Published in: BMC Infectious Diseases 1/2017

Open Access 01-12-2017 | Research article

Mortality in patients with HIV-1 and tuberculosis co-infection in Rio de Janeiro, Brazil - associated factors and causes of death

Authors: Rodrigo Otavio da Silva Escada, Luciane Velasque, Sayonara Rocha Ribeiro, Sandra Wagner Cardoso, Luana Monteiro Spindola Marins, Eduarda Grinsztejn, Maria Cristina da Silva Lourenço, Beatriz Grinsztejn, Valdiléa Gonçalves Veloso

Published in: BMC Infectious Diseases | Issue 1/2017

Login to get access

Abstract

Background

Tuberculosis is the most frequent opportunistic infection and the leading cause of death among persons living with HIV in several low and middle-income countries. Mortality rates during tuberculosis treatment and death causes among HIV-1/TB co-infected patients may differ based on the immunosuppression severity, timing of diagnosis and prompt initiation of tuberculosis and antiretroviral therapy.

Methods

This was a retrospective observational study conducted in the clinical cohort of patients with HIV-1/Aids of the National Institute of Infectious Diseases Evandro Chagas, Rio de Janeiro, Brazil. All HIV-1 infected patients who started combination antiretroviral therapy up to 30 days before or within 180 days after the start of tuberculosis treatment from 2000 to 2010 were eligible. Causes of death were categorized according to the "Coding Causes of Death in HIV” (CoDe) protocol. The Cox model was used to estimate the hazard ratio (HR) of selected mortality variables.

Results

A total of 310 patients were included. Sixty-four patients died during the study period. Mortality rate following tuberculosis treatment initiation was 44 per 100 person-years within the first 30 days, 28.1 per 100 person-years within 31 and 90 days, 6 per 100 person-years within 91 and 365 days and 1.6 per 100 person-years after 365 days. Death probability within one year from tuberculosis treatment initiation was approximately 13%. In the adjusted analysis the associated factors with mortality were: CD4 ≤ 50 cells/mm3 (HR: 3.10; 95% CI: 1.720 to 5.580; p = 0.00); mechanical ventilation (HR: 2.81; 95% CI: 1.170 to 6.760; p = 0.02); and disseminated tuberculosis (HR: 3.70; 95% CI: 1.290 to 10.590, p = 0.01). Invasive bacterial disease was the main immediate cause of death (46.9%).

Conclusion

Our results evidence the high morbidity and mortality among patients co-infected with HIV-1 and tuberculosis in Rio de Janeiro, Brazil. During the first year following tuberculosis diagnosis, mortality was the highest within the first 3 months, being invasive bacterial infection the major cause of death. In order to successfully intervene in this scenario, it is utterly necessary to address the social determinants of health contributing to the inequitable health care access faced by this population.
Literature
1.
go back to reference World Health Organization. Global tuberculosis report 2014. Geneva, Switzerland: World Health Organization; 2014. World Health Organization. Global tuberculosis report 2014. Geneva, Switzerland: World Health Organization; 2014.
2.
go back to reference De Oliveira GP, Torrens AW, Bartholomay P, Barreira D. Tuberculosis in Brazil: last ten years analysis – 2001–2010. Braz J Infect Dis. 2013;17:218–33.CrossRef De Oliveira GP, Torrens AW, Bartholomay P, Barreira D. Tuberculosis in Brazil: last ten years analysis – 2001–2010. Braz J Infect Dis. 2013;17:218–33.CrossRef
3.
go back to reference Guimarães RM. Lobo A de P, Siqueira EA, Borges TFF, Melo SCC. Tuberculose, HIV e pobreza: tendência temporal no Brasil, Américas e mundo. J Bras Pneumol. 2012;38:511–7. Guimarães RM. Lobo A de P, Siqueira EA, Borges TFF, Melo SCC. Tuberculose, HIV e pobreza: tendência temporal no Brasil, Américas e mundo. J Bras Pneumol. 2012;38:511–7.
4.
go back to reference Harries A, Hargreaves N, Gausi F, Kwanjana J, Salaniponi F. Others. High early death rate in tuberculosis patients in Malawi. Int. J Tuberc Lung Dis. 2001;5:1000–5. Harries A, Hargreaves N, Gausi F, Kwanjana J, Salaniponi F. Others. High early death rate in tuberculosis patients in Malawi. Int. J Tuberc Lung Dis. 2001;5:1000–5.
5.
go back to reference Cain KP, Anekthananon T, Burapat C, Akksilp S, Mankhatitham W, Srinak C, et al. Causes of death in HIV-infected persons who have tuberculosis. Thailand Emerg Infect Dis. 2009;15:258–64.CrossRefPubMed Cain KP, Anekthananon T, Burapat C, Akksilp S, Mankhatitham W, Srinak C, et al. Causes of death in HIV-infected persons who have tuberculosis. Thailand Emerg Infect Dis. 2009;15:258–64.CrossRefPubMed
6.
go back to reference Castelnuovo B, Manabe YC, Kiragga A, Kamya M, Easterbrook P, Kambugu A. Cause-specific mortality and the contribution of immune reconstitution inflammatory syndrome in the first 3 years after antiretroviral therapy initiation in an urban African cohort. Clin Infect Dis. 2009;49:965–72.CrossRefPubMed Castelnuovo B, Manabe YC, Kiragga A, Kamya M, Easterbrook P, Kambugu A. Cause-specific mortality and the contribution of immune reconstitution inflammatory syndrome in the first 3 years after antiretroviral therapy initiation in an urban African cohort. Clin Infect Dis. 2009;49:965–72.CrossRefPubMed
7.
go back to reference Kantipong P, Murakami K, Moolphate S, Aung MN, Yamada N. Causes of mortality among tuberculosis and HIV co-infected patients in Chiang Rai, Northern Thailand. HIVAIDS - Res. Palliat. Care. 2012;159. Kantipong P, Murakami K, Moolphate S, Aung MN, Yamada N. Causes of mortality among tuberculosis and HIV co-infected patients in Chiang Rai, Northern Thailand. HIVAIDS - Res. Palliat. Care. 2012;159.
8.
go back to reference Grinsztejn B, Veloso VG, Friedman RK, Moreira RI, Luz PM. Campos DP, et al. Early mortality and cause of deaths in patients using HAART in Brazil and the United States: AIDS. 2009;23:2107–14.PubMedPubMedCentral Grinsztejn B, Veloso VG, Friedman RK, Moreira RI, Luz PM. Campos DP, et al. Early mortality and cause of deaths in patients using HAART in Brazil and the United States: AIDS. 2009;23:2107–14.PubMedPubMedCentral
9.
go back to reference Moreira RI, Luz PM, Struchiner CJ, Morgado M, Veloso VG, Keruly JC, et al. Immune status at presentation for human immunodeficiency virus clinical care in Rio de Janeiro and Baltimore. J. Acquir. Immune Defic. Syndr. 1999. 2011;57:S171. Moreira RI, Luz PM, Struchiner CJ, Morgado M, Veloso VG, Keruly JC, et al. Immune status at presentation for human immunodeficiency virus clinical care in Rio de Janeiro and Baltimore. J. Acquir. Immune Defic. Syndr. 1999. 2011;57:S171.
10.
go back to reference Kowalska JD, Friis-Møller N, Kirk O, Bannister W, Mocroft A, Sabin C, et al. The Coding causes of death in HIV (CoDe) project: initial results and evaluation of methodology. Epidemiology. 2011;22:516–23.CrossRefPubMed Kowalska JD, Friis-Møller N, Kirk O, Bannister W, Mocroft A, Sabin C, et al. The Coding causes of death in HIV (CoDe) project: initial results and evaluation of methodology. Epidemiology. 2011;22:516–23.CrossRefPubMed
11.
go back to reference Grinsztejn B, Luz PM, Pacheco AG, Santos DVG, Velasque L, Moreira RI, et al. Changing Mortality Profile among HIV-Infected Patients in Rio de Janeiro, Brazil: Shifting from AIDS to Non-AIDS Related Conditions in the HAART Era. Yazdanpanah Y, editor. PLoS ONE. 2013;8:e59768. Grinsztejn B, Luz PM, Pacheco AG, Santos DVG, Velasque L, Moreira RI, et al. Changing Mortality Profile among HIV-Infected Patients in Rio de Janeiro, Brazil: Shifting from AIDS to Non-AIDS Related Conditions in the HAART Era. Yazdanpanah Y, editor. PLoS ONE. 2013;8:e59768.
13.
go back to reference Sharma SK, Mohan A. Extrapulmonary tuberculosis. Indian J Med Res. 2004;120:316–53.PubMed Sharma SK, Mohan A. Extrapulmonary tuberculosis. Indian J Med Res. 2004;120:316–53.PubMed
14.
go back to reference Schmaltz CAS, Sant’Anna FM, Neves SC, de Souza VL, Lourenço MC, Morgado MG, et al. Influence of HIV infection on mortality in a cohort of patients treated for tuberculosis in the context of wide access to HAART, in Rio de Janeiro, Brazil. JAIDS J Acquir Immune Defic Syndr. 2009;52:623–8. Schmaltz CAS, Sant’Anna FM, Neves SC, de Souza VL, Lourenço MC, Morgado MG, et al. Influence of HIV infection on mortality in a cohort of patients treated for tuberculosis in the context of wide access to HAART, in Rio de Janeiro, Brazil. JAIDS J Acquir Immune Defic Syndr. 2009;52:623–8.
15.
go back to reference Wang J-Y, Hsueh P-R, Wang S-K, Jan I-S, Lee L-N, Liaw Y-S, et al. Disseminated Tuberculosis: A 10-Year Experience in a Medical Center. Medicine (Baltimore). 2007;86:39–46. Wang J-Y, Hsueh P-R, Wang S-K, Jan I-S, Lee L-N, Liaw Y-S, et al. Disseminated Tuberculosis: A 10-Year Experience in a Medical Center. Medicine (Baltimore). 2007;86:39–46.
17.
go back to reference Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Intensive Care Med. 2003;29:530–8.CrossRefPubMed Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Intensive Care Med. 2003;29:530–8.CrossRefPubMed
19.
go back to reference Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, Qasba SS, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 2011;365:1482–91.CrossRefPubMedPubMedCentral Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, Qasba SS, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 2011;365:1482–91.CrossRefPubMedPubMedCentral
20.
go back to reference Kleinbaum DG. Klein M. Survival analysis: Springer; 1996. Kleinbaum DG. Klein M. Survival analysis: Springer; 1996.
21.
go back to reference Therneau T. A Package for Survival Analysis in S. R package version 2.37–7. 2014. Therneau T. A Package for Survival Analysis in S. R package version 2.37–7. 2014.
22.
go back to reference Podlekareva DN, Efsen AMW, Schultze A, Post FA, Skrahina AM, Panteleev A, et al. Tuberculosis-related mortality in people living with HIV in Europe and Latin America: an international cohort study. Lancet HIV. 2016;3:e120–31.CrossRefPubMed Podlekareva DN, Efsen AMW, Schultze A, Post FA, Skrahina AM, Panteleev A, et al. Tuberculosis-related mortality in people living with HIV in Europe and Latin America: an international cohort study. Lancet HIV. 2016;3:e120–31.CrossRefPubMed
23.
go back to reference Podlekareva DN, Mocroft A, Post FA, Riekstina V, Miro JM. Furrer H, et al. Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina: AIDS. 2009;23:2485–95.PubMed Podlekareva DN, Mocroft A, Post FA, Riekstina V, Miro JM. Furrer H, et al. Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina: AIDS. 2009;23:2485–95.PubMed
24.
go back to reference Lawn SD, Harries AD, Meintjes G, Getahun H, Havlir DV. Wood R. Reducing deaths from tuberculosis in antiretroviral treatment programmes in sub-Saharan Africa: AIDS. 2012;26:2121–33.PubMed Lawn SD, Harries AD, Meintjes G, Getahun H, Havlir DV. Wood R. Reducing deaths from tuberculosis in antiretroviral treatment programmes in sub-Saharan Africa: AIDS. 2012;26:2121–33.PubMed
25.
go back to reference Golub JE, Saraceni V, Cavalcante SC, Pacheco AG, Moulton LH, King BS, et al. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro. Brazil AIDS Lond Engl. 2007;21:1441.CrossRef Golub JE, Saraceni V, Cavalcante SC, Pacheco AG, Moulton LH, King BS, et al. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro. Brazil AIDS Lond Engl. 2007;21:1441.CrossRef
26.
go back to reference De Pinho AM, Santoro-Lopes G, Harrison LH, Schechter M. Chemoprophylaxis for tuberculosis and survival of HIV-infected patients in Brazil. AIDS. 2001;15:2129–35.CrossRefPubMed De Pinho AM, Santoro-Lopes G, Harrison LH, Schechter M. Chemoprophylaxis for tuberculosis and survival of HIV-infected patients in Brazil. AIDS. 2001;15:2129–35.CrossRefPubMed
27.
go back to reference De Loureiro MM, Leborato Guerra R, Cailleaux-Cezar M, Eric Golub J, Barreto CM. Time from symptom onset to the initiation of treatment of pulmonary tuberculosis in a city with a high incidence of the disease. J. Bras. Pneumol. Publicacao of. Soc. Bras. Pneumol. E Tisilogia. 2012;38:202–9. De Loureiro MM, Leborato Guerra R, Cailleaux-Cezar M, Eric Golub J, Barreto CM. Time from symptom onset to the initiation of treatment of pulmonary tuberculosis in a city with a high incidence of the disease. J. Bras. Pneumol. Publicacao of. Soc. Bras. Pneumol. E Tisilogia. 2012;38:202–9.
28.
go back to reference Storla DG, Yimer S, Bjune GA. A systematic review of delay in the diagnosis and treatment of tuberculosis. BMC Public Health. 2008;8:15–5. Storla DG, Yimer S, Bjune GA. A systematic review of delay in the diagnosis and treatment of tuberculosis. BMC Public Health. 2008;8:15–5.
29.
go back to reference Schmaltz CAS, Santoro-Lopes G, Lourenço MC, Morgado MG, Velasque L de S, Rolla VC. Factors Impacting Early Mortality in Tuberculosis/HIV Patients: Differences between Subjects Naïve to and Previously Started on HAART. Pai M, editor. PLoS ONE. 2012;7:e45704. Schmaltz CAS, Santoro-Lopes G, Lourenço MC, Morgado MG, Velasque L de S, Rolla VC. Factors Impacting Early Mortality in Tuberculosis/HIV Patients: Differences between Subjects Naïve to and Previously Started on HAART. Pai M, editor. PLoS ONE. 2012;7:e45704.
30.
go back to reference Marcy O, Laureillard D, Madec Y, Chan S, Mayaud C, Borand L, et al. Causes and determinants of mortality in HIV-infected adults with tuberculosis: an analysis from the CAMELIA ANRS 1295-CIPRA KH001 randomized trial. Clin Infect Dis. 2014;59:435–45.CrossRefPubMedPubMedCentral Marcy O, Laureillard D, Madec Y, Chan S, Mayaud C, Borand L, et al. Causes and determinants of mortality in HIV-infected adults with tuberculosis: an analysis from the CAMELIA ANRS 1295-CIPRA KH001 randomized trial. Clin Infect Dis. 2014;59:435–45.CrossRefPubMedPubMedCentral
31.
go back to reference Kwara A, Roahen-Harrison S, Prystowsky E, Kissinger P, Adams R, Mathison J, et al. Manifestations and outcome of extra-pulmonary tuberculosis: impact of human immunodeficiency virus co-infection. Int J Tuberc Lung Dis. 2005;9:485–93.PubMed Kwara A, Roahen-Harrison S, Prystowsky E, Kissinger P, Adams R, Mathison J, et al. Manifestations and outcome of extra-pulmonary tuberculosis: impact of human immunodeficiency virus co-infection. Int J Tuberc Lung Dis. 2005;9:485–93.PubMed
32.
go back to reference Whalen C, Horsburgh CR Jr, Hom D, Lahart C, Simberkoff M, Ellner J. Site of disease and opportunistic infection predict survival in HIV-associated tuberculosis. AIDS. 1997;11:455–60.CrossRefPubMed Whalen C, Horsburgh CR Jr, Hom D, Lahart C, Simberkoff M, Ellner J. Site of disease and opportunistic infection predict survival in HIV-associated tuberculosis. AIDS. 1997;11:455–60.CrossRefPubMed
33.
go back to reference Lawn SD, Wilkinson RJ, Lipman MCI, Wood R. Immune reconstitution and “unmasking” of tuberculosis during antiretroviral therapy. Am J Respir Crit Care Med. 2008;177:680–5.CrossRefPubMedPubMedCentral Lawn SD, Wilkinson RJ, Lipman MCI, Wood R. Immune reconstitution and “unmasking” of tuberculosis during antiretroviral therapy. Am J Respir Crit Care Med. 2008;177:680–5.CrossRefPubMedPubMedCentral
34.
go back to reference Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, Tahirli R, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet. 2011;377:1495–505.CrossRefPubMedPubMedCentral Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, Tahirli R, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet. 2011;377:1495–505.CrossRefPubMedPubMedCentral
36.
go back to reference Wong EB, Omar T, Setlhako GJ, Osih R, Feldman C, Murdoch DM, et al. Causes of death on antiretroviral therapy: a Post-mortem study from South Africa. PLoS One. 2012;7:e47542.CrossRefPubMedPubMedCentral Wong EB, Omar T, Setlhako GJ, Osih R, Feldman C, Murdoch DM, et al. Causes of death on antiretroviral therapy: a Post-mortem study from South Africa. PLoS One. 2012;7:e47542.CrossRefPubMedPubMedCentral
37.
go back to reference Gutierrez E, Trevisan ZD, Nascimento Saldiva P, Capelozzi V. Autopsy-proven determinants of death in HIV-infected patients treated for pulmonary tuberculosis in Sao Paulo. Brazil Pathol Res Pract. 2002;198:339–46(8).CrossRefPubMed Gutierrez E, Trevisan ZD, Nascimento Saldiva P, Capelozzi V. Autopsy-proven determinants of death in HIV-infected patients treated for pulmonary tuberculosis in Sao Paulo. Brazil Pathol Res Pract. 2002;198:339–46(8).CrossRefPubMed
40.
go back to reference Japiassú AM, Amâncio RT, Mesquita EC, Medeiros DM, Bernal HB, Nunes EP, et al. Sepsis is a major determinant of outcome in critically ill HIV/AIDS patients. Crit Care. 2010;14:R152–2. Japiassú AM, Amâncio RT, Mesquita EC, Medeiros DM, Bernal HB, Nunes EP, et al. Sepsis is a major determinant of outcome in critically ill HIV/AIDS patients. Crit Care. 2010;14:R152–2.
41.
go back to reference Wiktor SZ, Sassan-Morokro M, Grant AD, Abouya L, Karon JM, Maurice C, et al. Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, cote d’Ivoire: a randomised controlled trial. Lancet. 1999;353:1469–75.CrossRefPubMed Wiktor SZ, Sassan-Morokro M, Grant AD, Abouya L, Karon JM, Maurice C, et al. Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, cote d’Ivoire: a randomised controlled trial. Lancet. 1999;353:1469–75.CrossRefPubMed
42.
go back to reference Nunn AJ, Mwaba P, Chintu C, Mwinga A, Darbyshire JH, Zumla A, et al. Role of co-trimoxazole prophylaxis in reducing mortality in HIV infected adults being treated for tuberculosis: randomised clinical trial. BMJ. 2008;337:a257–7. Nunn AJ, Mwaba P, Chintu C, Mwinga A, Darbyshire JH, Zumla A, et al. Role of co-trimoxazole prophylaxis in reducing mortality in HIV infected adults being treated for tuberculosis: randomised clinical trial. BMJ. 2008;337:a257–7.
43.
go back to reference Harries AD, Zachariah R, Lawn SD. Providing HIV care for co-infected tuberculosis patients: a perspective from sub-Saharan Africa [State of the art series. Tuberculosis. Edited by ID Rusen. Number 3 in the series]. Int. J. Tuberc. Lung Dis. 2009;13:6–16. Harries AD, Zachariah R, Lawn SD. Providing HIV care for co-infected tuberculosis patients: a perspective from sub-Saharan Africa [State of the art series. Tuberculosis. Edited by ID Rusen. Number 3 in the series]. Int. J. Tuberc. Lung Dis. 2009;13:6–16.
44.
go back to reference Grinsztejn B, Hosseinipour MC, Ribaudo HJ, Swindells S, Eron J, Chen YQ, et al. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis. 2014;14:281–90.CrossRefPubMedPubMedCentral Grinsztejn B, Hosseinipour MC, Ribaudo HJ, Swindells S, Eron J, Chen YQ, et al. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis. 2014;14:281–90.CrossRefPubMedPubMedCentral
45.
go back to reference The INSIGHT START. Study group. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection N Engl J Med. 2015;373:795–807. The INSIGHT START. Study group. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection N Engl J Med. 2015;373:795–807.
46.
go back to reference The TEMPRANO ANRS. 12136 study group. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa N Engl J Med. 2015;373:808–22. The TEMPRANO ANRS. 12136 study group. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa N Engl J Med. 2015;373:808–22.
47.
go back to reference Paim J, Travassos C, Almeida C, Bahia L, Macinko J. The Brazilian health system: history, advances, and challenges. Lancet. 2011;377:1778–97.CrossRefPubMed Paim J, Travassos C, Almeida C, Bahia L, Macinko J. The Brazilian health system: history, advances, and challenges. Lancet. 2011;377:1778–97.CrossRefPubMed
Metadata
Title
Mortality in patients with HIV-1 and tuberculosis co-infection in Rio de Janeiro, Brazil - associated factors and causes of death
Authors
Rodrigo Otavio da Silva Escada
Luciane Velasque
Sayonara Rocha Ribeiro
Sandra Wagner Cardoso
Luana Monteiro Spindola Marins
Eduarda Grinsztejn
Maria Cristina da Silva Lourenço
Beatriz Grinsztejn
Valdiléa Gonçalves Veloso
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2017
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-017-2473-y

Other articles of this Issue 1/2017

BMC Infectious Diseases 1/2017 Go to the issue